Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 801–900 of 1,000
Emerging Translatable Safety Biomarkers
Tarrant, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12387-x · Cited by 11
Advancing Psychiatric Pharmacogenomics Using Drug Development Paradigms
Smith, R. M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0104 · Cited by 9
CDx, NGS and regulation: five perspectives from the Pistoia Alliance
Wise, J. A., Furness, M., McWilliams, S., & Patton, S. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.002 · Cited by 7
Target discovery using biobanks and human genetics
Hicks, M. A., Hou, C., Iranmehr, A., Marosi, K., & Kirkness, E. F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.014 · Cited by 7
Delaunois, A. G., Accardi, M. V., André, V., Authier, S., Bouzom, F., Hebeisen, S., Lamberty, Y., Laredj-Bourezg, F., Leclercq, K., Letombe, A.-G., et al. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106874 · Cited by 8
Organ-on-a-chip: Its use in cardiovascular research
Lim, S., Kim, S. W., Kim, I., Song, B., & Lee, S. (2022) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-221428 · Cited by 8
Making the most effective use of available computational methods for drug repositioning
Gori, D. N. P., Alberca, L. N., & Talevi, A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2198700 · Cited by 10
“Moreover, inappropriate PK/PD explained around 15% of closures at Phase I and about one third of the ‘lack of efficacy’ cases could be explained by inadequate exposure to the drug [7].”
BackgroundEmerging concepts towards a translational framework in Alzheimer’s disease
Cozachenco, D., Zimmer, E. R., & Lourenco, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105246 · Cited by 8
Yu, J.-E., You, B. H., Bae, M., Han, S. Y., Jung, K., & Choi, Y. H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082167 · Cited by 7
O’Connor, E. C., Kambara, K., & Bertrand, D. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2270902 · Cited by 7
“Concepts such as AstraZeneca’s ‘five R’s framework’ [118] (right target, right tissue, right safety, right patient, and right commercial potential), Pfizer’s ‘3 Pillar’ paradigm (ensuring exposure at the site of action, binding to the pharmacological target and expression of pharmacological…”
BackgroundRao, D. B., Pardo, I. D. R., Chang, J., Bolon, B. N., & Garman, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-821046-8.00007-4 · Cited by 8
Contractile Force Readout of hESC-Cardiomyocytes
Oleaga, C., Legters, G., Bridges, L. R., Kumanchik, L., Martin, C., Cai, Y., Schnepper, M. T., McAleer, C. W., Long, C. J., & Hickman, J. J. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_12 · Cited by 7
Ligand-Binding Kinetics on Histamine Receptors
Bosma, R., Mocking, T. A. M., Leurs, R., & Vischer, H. F. (2017) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6843-5_5 · Cited by 10
Towards knowledge-driven cross-species extrapolation
Thiel, C., Hofmann, U., Ghallab, A., Gebhardt, R., Hengstler, J. G., & Kuepfer, L. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.02.008 · Cited by 9
Future Directions of Genomics Research in Rheumatic Diseases
Okada, Y., Kishikawa, T., Sakaue, S., & Hirata, J. (2017) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2017.04.009 · Cited by 7
“Retrospective studies investigating drug discovery pipelines and clinical trial results suggested that utilization of disease-associated gene information should improve the productivity.(44,45) As empirical evidence to support this hypothesis, the authors’ in silico networkbased analysis demonstrated that RA risk gene…”
Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma
Mascaro-Cordeiro, B., Oliveira, I. D., Tesser‐Gamba, F., Pavon, L. F., Saba‐Silva, N., Cavalheiro, S., Dastoli, P. A., & de Toledo, S. R. C. (2018) · Child s Nervous System · doi:10.1007/s00381-018-3817-7 · Cited by 7
Kiani, Y. S., & Jabeen, I. (2019) · Computation · doi:10.3390/computation7020026 · Cited by 8
“Various proofs of concept examples of the application of the “5R” strategy indicates an improved success rate from candidate selection to the completion of phase III [2,3].”
BackgroundShould the United States government regulate prescription prices? A critical review
Patterson, J. A., & Carroll, N. V. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.06.010 · Cited by 9
Venkatasubramanian, R., Collins, T. A., Lesko, L. J., Mettetal, J. T., & Trame, M. N. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15079 · Cited by 7
“Cardiovascular safety is a major reason for black box warnings and post approval drug withdrawal from the market (Cook et al., 2014; Kola & Landis, 2004; Munos, 2009).”
BackgroundMatsui, T., Miyamoto, N., Saito, F., & Shinozawa, T. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200422090952 · Cited by 6
Rana, P., Kogut, S. J., Wen, X., Akhlaghi, F., & Aleo, M. D. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00040 · Cited by 8
Koukouli, E., Wang, D. Y. Q., Dondelinger, F., & Park, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008066 · Cited by 8
“rapidly lethal diseases are expensive, complex and often lead to failure due to lack of 7 efficacy [2].”
BackgroundBergauer, T., Ruppert, T., Essioux, L., & Spleiss, O. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016651298 · Cited by 10
“Failures of drugs due to insufficient efficacy are responsible for 51% of clinical phase II and 66% of clinical phase III failures.10,11 As an example, selecting the ‘‘right target’’ was one crucial factor in the 5 R framework, which recently emerged from a retrospective analysis of failures in drug development progra…”
BackgroundJeong, C. G., Negro, G. D., Getsios, S., & Ekert, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00005-0 · Cited by 13
Trends in interorganizational transactions in personalized medicine development
Makino, T., Sengoku, S., Ishida, S., & Kodama, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.022 · Cited by 7
Technical aspects of megaureter repair.
Hendren, W. H. (1977) · PubMed · Cited by 9
Attrition in Drug Discovery and Development
Boyer, S. K., BREALEY, C. J., & Davis, A. M. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch1 · Cited by 9
Human iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Therapeutic potential of targeting ubiquitin-specific proteases in colorectal cancer
Oon, C. E., Anbazhagan, P., & Tan, C. T. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104356 · Cited by 6
Zhao, X., Liu, D., Li, G., Xu, W., & Wu, G. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s570411 · Cited by 10
“161 Even setting aside R&D risks, the complex formulation systems and lengthy preparation processes of nanoparticles still result in high production costs.”
Toward Integrative Predictive Toxicology: Advanced Methods for Drug Toxicity and Safety Prediction
Gianquinto, E., Bersani, M., Armando, L. G., Davani, L., Cena, C., Simone, A. D., & Spyrakis, F. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70065 · Cited by 12
The evolving global landscape of first-in-class oncology drug innovation
Mao, X., Wang, Z., Kong, S., Yang, Y., Dreyer, N. A., Ba, Y., Lotze, M. T., Zhan, Q., & Li, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02606-7 · Cited by 8
Investigative safety strategies to improve success in drug development
Atienzar, F., Delaunois, A. G., Brouta, F., Cornet, M., Fleurance, R., Gerets, H. H. J., Glineur, S., Hasselgren, C., Kießling, A., da Costa, A. N., et al. (2016) · JOURNAL OF MEDICINES DEVELOPMENT SCIENCES · doi:10.18063/jmds.v2i1.139 · Cited by 14
Nord, M., Ysander, M., Sullivan, T., & Patel, M. A. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200082 · Cited by 6
“Examples of pre-existing analyses include a root cause analysis of safety failures in early clinical studies carried out as part of the analysis of early development performance inAstraZeneca as already described [9].”
BackgroundMethodRoberts, R. A., Campbell, R. A., Sikakana, P., Sadler, C., Osier, M. R., Xu, Y., Feng, J. Y., Mitchell, M. L., Sakowicz, R., Chester, A. E., et al. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab073 · Cited by 6
“The first consideration was the target itself since around 40% of drug development failures attributable to safety are associated with target (Cook et al., 2014).”
BackgroundAl-Amin, R. A., Johansson, L., Abdurakhmanov, E., Landegren, N., Löf, L., Arngården, L., Blokzijl, A., Svensson, R., Hammond, M., Lönn, P., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac842 · Cited by 6
“circles that template localized RCA reactions, the products of which are visualized using fluorescent oligonucleotide probes (3).”
BackgroundBové, D. S., Seibold, H., Boulesteix, A., Manitz, J., Gasparini, A., Günhan, B. K., Boix, O., Schüler, A., Fillinger, S., Nahnsen, S., et al. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104613 · Cited by 8
Takahashi, K., Ishibashi, Y., Chujo, K., Suzuki, I., & Sato, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612605 · Cited by 7
The Impact of Cellular Environment on In Vitro Drug Screening
Moldasheva, A., Bakyt, L., Bulanin, D. S., & Aljofan, M. (2023) · Future Science OA · doi:10.2144/fsoa-2023-0027 · Cited by 9
“A report that analyzed a five-year period (2005–2010) for AstraZeneca portfolio performance of drug failure, suggested that more than 70% of developmental drugs fail in stage II studies and less than 10% in preclinical stage [3] .”
BackgroundADME Optimization in Drug Discovery
McGinnity, D. F., & Grime, K. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00298 · Cited by 9
Challenges in Drug Development for Neurological Disorders
Guha, L., Singh, N., & Kumar, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_2 · Cited by 12
Waqas, M. S., Ullah, S. M., Ullah, A., Halim, S. A., Rehman, N. U., Khalid, A., Ali, A., Khan, A., Gibbons, S., Csük, R., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134476 · Cited by 6
Bonaccorsi, S. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673476-00461 · Cited by 10
Open innovation in neuroscience research and drug discovery
Hunter, A. J., Lee, W. H., & Bountra, C. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818799270 · Cited by 6
“The lack of R&D in psychiatric disease is a reflection, in part, of the lack of validated biomarkers and animal models as well poor disease understanding (Cook et al., 2014).”
BackgroundInnovative models for in vitro detection of seizure
Rockley, K. L., Roberts, R. A., & Morton, M. J. (2019) · Toxicology Research · doi:10.1039/c9tx00210c · Cited by 6
Bowen, T. J., Hall, A. R., Lloyd, G. R., Weber, R. J. M., Wilson, A., Pointon, A., & Viant, M. R. (2021) · Metabolites · doi:10.3390/metabo11090644 · Cited by 7
How translational modeling in oncology needs to get the mechanism just right
Yates, J. W. T., & Fairman, D. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.13183 · Cited by 7
You, D., Cohen, J. D., Pustovalova, O., Lewis, L., & Shen, L. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac011 · Cited by 8
“221 Neurotoxicity accounts for approximately a quarter of adverse effects observed in clinical trials and is the third leading cause of safety-related drug attrition (Cook et al., 2014; Monticello et al., 2017; Walker et al., 2018).”
Ligand–Receptor Binding Kinetics in Drug Design
Borisov, D. V., & Veselovsky, A. V. (2020) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075082003004x · Cited by 6
History and Present Scenario of Computers in Pharmaceutical Research and Development
Saharan, V. A., Banerjee, S., Penuli, S., & Dobhal, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-5180-9_1 · Cited by 6
The potassium channels: Neurobiology and pharmacology of tinnitus
Lai, H., Gao, M., & Yang, H. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25281 · Cited by 9
“Reports on reasons for Phase 2 and 3 failures suggested that a human genetic relationship between the target and the disease indication could increase the percentage of successful Phase 2 and 3 trials (Cook et al., 2014; Morgan et al., 2018 ).”
BackgroundOishi, M., Sayama, H., Toshimoto, K., Nakayama, T., & Nagasaka, Y. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101020 · Cited by 7
Sharma, A. K., Morrison, J. P., Rao, D. B., Pardo, I. D. R., Garman, R. H., & Bolon, B. N. (2016) · International Journal of Toxicology · doi:10.1177/1091581816636372 · Cited by 6
Dutton, P., Love, S., Billingham, L. J., & Hassan, A. B. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280216662070 · Cited by 7
“This paper does not discuss the use of other non-informative prior distributions (such as the improper prior Betað0, 0Þ or Jeffrey’s prior (Betað12 , 12Þ).”
BackgroundMethodInfluentialScreening for Target Engagement using the Cellular Thermal Shift Assay - CETSA
Axelsson, H., Almqvist, H., Seashore-Ludlow, B. A., & Lundbäck, T. (2016) · Europe PMC (PubMed Central) · Cited by 6
Quantification of In Vivo Target Engagement Using Microfluidic Activity-Based Protein Profiling
Reardon, H. T., Herbst-Graham, R. A., Henry, C. L., Herbst, D. M., Ngo, N., Cisar, J. S., Weber, O. D., Niphakis, M. J., & O’Neill, G. P. (2019) · SLAS TECHNOLOGY · doi:10.1177/2472630319852303 · Cited by 8
Pieterse, C. L., Rungger, I., Gilmore, I. S., Wickramasinghe, R. C., & Hanley, L. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02365 · Cited by 6
High-Throughput Cell Toxicity Assays
Murray, D., McWilliams, L. J., & Wigglesworth, M. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3673-1_16 · Cited by 11
Has molecular imaging delivered to drug development?
Murphy, P. S., Patel, N., & McCarthy, T. J. (2017) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2017.0112 · Cited by 5
The Promise of Open Innovation in Drug Discovery: An Industry Perspective
Rees, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.125 · Cited by 6
Turner, M. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.005 · Cited by 6
Eulogy for the Metabolic Clinical Investigator?
Vella, A. V., Jensen, M. D., & Nair, K. S. (2016) · Diabetes · doi:10.2337/db16-0923 · Cited by 6
“(17) reported that drug development projects were more likely to succeed if biomarkers of efficacy were available at the start of phase 2 studies or if there was genetic evidence linking the drug target to the targeted disease.”
BackgroundDang, C., Feng, Z., Xu, T., Li, M., Wang, Z., Song, H. L., & Wang, R. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00013 · Cited by 5
Innovation versus Financialization in the US Pharmaceutical Industry
Tulum, Ö., & Lazonick, W. H. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009708012 · Cited by 5
Park, M., Song, W., Ahn, H., & Kim, S. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105994 · Cited by 7
“2 Accordingly, the relationship between characteristics of genes and toxicity has been extensively studied across various biological contexts such as gene essentiality, 10–12 tissue specificity, 13,14 and connectivity within biological networks.”
Proposed key characteristics of neurotoxic chemicals
Lein, P. J., Bowman, A. B., Cao, Z., Carson, M. J., Eskenazi, B., Fritsche, E., Harry, G. J., Härtung, T., Pessah, I. N., Slikker, W., et al. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.103370 · Cited by 7
Zhang, E. S., Osipenko, L., & Hickman, J. A. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-001037 · Cited by 6
“For trials performed purely by academic institutions, as in Jentzsch et al , 8 two fractions of the cost of trials performed in the USA by industry were arbitrarily taken (0.5 and 0.1) giving an estimated range of costs as a fraction of those of industry.”
InfluentialMicroengineering the Liver: Strategies for Constructing Functional Liver‐on‐a‐Chip Devices
Wang, J., Liang, Z., Wang, J., Li, Z., Wang, S., Wei, Y., Xie, X., & Huang, D. (2026) · Exploration · doi:10.1002/exp2.70137 · Cited by 6
Leung, H., Duan, C., Gou, W., Chen, J., Xin, Y., Zheng, Z., Naumov, V., Gennert, D. G., Zhang, M., Aliper, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47765-3 · Cited by 7
Light, D. S., Aleo, M. D., & Kenna, J. G. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_17 · Cited by 6
A novel in vitro high-content imaging assay for the prediction of drug-induced lung toxicity
Fitzpatrick, P. A., Johansson, J., Maglennon, G. A., Wallace, I., Hendrickx, R., Stamou, M., Sivars, K. B., Busch, S., Johansson, L., van Zuydam, N. R., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03800-8 · Cited by 5
“The development of innovative inhaled medicines is often impacted by toxicity in the respiratory tract in non-clinical species, leading to attrition or dose limitations in clinic, typically after the selection of novel drug candidates (David et al. 2014).”
BackgroundTakeshita, J., Goto, Y., Yamamoto, S., Sasaki, T., & Yoshinari, K. (2024) · Critical Reviews in Toxicology · doi:10.1080/10408444.2024.2427221 · Cited by 5
“Compared with the organ systems associated with safety failures in the preclinical stages of drug candidates (Cook et al. 2014), the liver, kidney, and stomach were common, but the heart, musculoskeletal, and central nervous systems did not appear in industrial chemicals.”
Quantitative Systems Pharmacology Development and Application in Neuroscience
Geerts, H. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2024_739 · Cited by 6
Translational Research on Amyotrophic Lateral Sclerosis (ALS): The Preclinical SOD1 Mouse Model
Mina, M., Konsolaki, E., & Zagoraiou, L. (2018) · Journal of Translational Neurosciences · doi:10.21767/2573-5349.100022 · Cited by 6
Caenorhabditis elegans-on-a-chip: microfluidic platforms for high-resolution imaging and phenotyping
Mondal, S., & Ben‐Yakar, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00009-7 · Cited by 5
Biosimilars: development and investigation using achievements in modern biotechnology
Niyazov, R. R., Dranitsyna, M. A., Vasiliev, A. N., & Gavrishina, E. V. (2021) · Diabetes Mellitus · doi:10.14341/dm12576 · Cited by 5
Campanella, B., Colombaioni, L., Nieri, R., Benedetti, E., Onor, M., & Bramanti, E. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.621548 · Cited by 6
“The metabolic state of the cells depends on nutrients’ concentrations, oxygenation, pH, and cell density (Cook et al., 2014; Wright Muelas et al., 2018), and cell metabolism is critical in cell growth and survival.”
BackgroundToxic nephropathy: Adverse renal effects caused by drugs
Unwin, R. J. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.09.008 · Cited by 6
Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs
Bieber, J. M., Sanman, L. E., Sun, X., Hammerlindl, H., Bao, F., Roth, M. A., Koleske, M. L., Huang, L., Aweeka, F., Wu, L. F., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03048-x · Cited by 5
Saito, R., & Nakada, T. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101019 · Cited by 6
When the drugs (don’t) work: The role of science in product commercialization
Anckaert, P. (2025) · Research Policy · doi:10.1016/j.respol.2025.105237 · Cited by 5
The Importance of Biological Invariance in Drug Design
Luis, F. M. J. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.18.003086 · Cited by 5
“To allow Precision Medicine, genomic kits are needed to easier diagnosis and adopt optimum decisions [2].”
BackgroundHipótese amiloide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados.
Delanogare, E., Flores, D., de Souza, R. M., Souza, L. D., & Moreira, E. L. G. (2019) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v31i1.8395 · Cited by 16
In vitro models for accurate prediction of renal tubular xenobiotic transport in vivo
Vriend, J., Pye, K., & Brown, C. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.12.001 · Cited by 6
Oda, S., Hirabuki, Y., Takeuchi, T., Kagawa, T., & Yokoi, T. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4144 · Cited by 5
“drawal of an approved drug from the market (Cook et al., 2014; Watkins, 2011).”
BackgroundOrrù, V., Steri, M., Cucca, F., & Fiorillo, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714461 · Cited by 5
High-throughput Measurement of Gut Transit Time Using Larval Zebrafish
Cassar, S. C., Huang, X., & Cole, T. (2018) · Journal of Visualized Experiments · doi:10.3791/58497-v · Cited by 5
Model Systems in Endometriosis Research: Translation, Translation, Translation!
Groothuis, P. G. (2022) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.809366 · Cited by 5
Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models
Brigo, A., Naga, D., & Muster, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_24 · Cited by 5
Stellari, F. F., Ruscitti, F., Ravanetti, F., Essers, J., Ridwan, Y. R., Belenkov, S., Vos, W. G., Ferreira, F., KleinJan, A., van Heijningen, P., et al. (2017) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2017.230 · Cited by 5
Wang, Z.-Z., Yi, C., Huang, J., Xu, T., Chen, K.-Z., Wang, Z., Xue, Y., Lu, J.-L., Nie, B., Zhang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01339 · Cited by 5
Utilizing Selection Biomarkers in Clinical Trials: Is This the Future of Drug Development?
Carroll, A. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0174 · Cited by 5
Kiyosawa, N., & Manabe, S. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.sp15 · Cited by 5
“Thus, the network modeling technique can add value to disease profi ling results for investigating potential key driver pathways in a pathophysiological condition and support selection of right drug target, which is the basis for successful drug development (Cook et al., 2014).”
BackgroundIntegration of systems biology with organs-on-chips to humanize therapeutic development
Edington, C., Cirit, M., Chen, W. L. K., Clark, A. M., Wells, A. H., Trumper, D. L., & Griffith, L. G. (2017) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2256078 · Cited by 5
In vivo MR in the drug pipeline
Evelhoch, J. L. (2018) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2018.04.012 · Cited by 5
Assessing drug target suitability using TargetMine
Chen, Y.-A., Yogo, E., Kurihara, N., Ohno, T., Higuchi, C., Rokushima, M., & Mizuguchi, K. (2019) · F1000Research · doi:10.12688/f1000research.18214.1 · Cited by 6
Biomonitoring and Digital Data Technology as an Opportunity for Enhancing Animal Study Translation
Defensor, E. B., Lim, M. A., & Schaevitz, L. R. (2021) · ILAR Journal · doi:10.1093/ilar/ilab018 · Cited by 4
Olla, S., Steri, M., Formato, A., Whalen, M. B., Corbisiero, S., & Agresti, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122064 · Cited by 6
“It is now widely accepted that the selection of targets based on genetics significantly increases the success rates of clinical development programs [15,16].”
BackgroundMaciejewski, M., Lounkine, E., Whitebread, S., Farmer, P. J., DuMouchel, B., Shoichet, B. K., & Urbán, L. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/068692 · Cited by 6
“Several important events occurred over the clinical life of rofecoxib since its approval by the FDA in 1999: (1) A clinical study by Bombardier et al.”
BackgroundStewart, A. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00008 · Cited by 5
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.